SCHEMBL2819903

SCHEMBL2819903

CCc1nc2cc(Cl)c(F)cc2c(OC(=O)C2CC2)c1C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.36
ABL1 P00519 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
GRM1 Q13255 3/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GAA P10253 1/20 0.32
HSD11B1 P28845 1/20 0.32
CA2 P00918 1/20 0.32
ACACB O00763 1/20 0.32
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
VCAM1 P19320 1/20 0.31
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819937 0.91 USP2 (0.38) USP2KDM4EGRM1MEN1KMT2A
SCHEMBL2823000 0.87 USP2 (0.37) USP2SMN1; SMN2KDM4EGRM1MEN1
SCHEMBL2821034 0.86 PTGS2 (0.33) ABL1SMN1; SMN2KDM4EPOLBTSHR
SCHEMBL2823400 0.85 GAA (0.33) KDM4EMEN1KMT2AGAACA2
SCHEMBL8127056 0.82 USP2 (0.41) USP2POLBGRM1MEN1KMT2A
SCHEMBL2820547 0.80 ALDH1A1 (0.32) SMN1; SMN2KDM4EMEN1KMT2AGAA
SCHEMBL2823475 0.78 USP2 (0.36) USP2ABL1SMN1; SMN2KDM4EPOLB
SCHEMBL2819625 0.77 GAA (0.37) USP2KDM4ETSHRMEN1KMT2A
SCHEMBL2825212 0.77 HPGD (0.34) SMN1; SMN2KDM4ETSHRMEN1KMT2A
SCHEMBL2820533 0.77 L3MBTL1 (0.34) SMN1; SMN2KDM4EGRM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C USP2 1504/4885ABL1 33/4885SMN1; SMN2 3246/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 USP2 3624/4885ABL1 756/4885SMN1; SMN2 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.